<p>Aclaris Therapeutics（纳斯达克股票代码：ACRS - 获取免费报告）在周一发布的报告中被 Guggenheim 的投资分析师上调至 “强力买入” 评级，Zacks.com 报道。</p>
<p>获取 <strong>Aclaris Therapeutics</strong> 的提醒：</p>
<ul>
<li>3 只被低估的制药股，具备上涨催化剂</li>
</ul>
<p>ACRS 已经成为其他几份报告的主题。华尔街 Zen 在 4 月 12 日的研究报告中将 Aclaris Therapeutics 的评级从 “持有” 下调至 “卖出”。Piper Sandler 在周二将 Aclaris Therapeutics 的目标价从 7.00 美元上调至 11.00 美元，并给予该股票 “超配” 评级。Weiss Ratings 在 3 月 27 日的研究报告中重申了对 Aclaris Therapeutics 的 “卖出（d-）” 评级。瑞银集团在 4 月 16 日的报告中设定了 Aclaris Therapeutics 的目标价为 10.00 美元。最后，Craig Hallum 在 1 月 30 日的研究报告中开始覆盖 Aclaris Therapeutics。他们给予该公司 “买入” 评级和 10.00 美元的目标价。两位股票研究分析师给予该股票 “强力买入” 评级，五位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “买入”，平均目标价为 11.00 美元。</p>
<p><strong>查看我们对 ACRS 的最新股票分析</strong></p>
<h2>Aclaris Therapeutics 股票表现</h2>
<p>纳斯达克：ACRS 的股票在周一开盘价为 4.75 美元。Aclaris Therapeutics 的年低为 1.16 美元，年高为 4.89 美元。该股票的市值为 6.6339 亿美元，市盈率为-8.96，贝塔值为 0.76。该公司 50 日简单移动平均线为 3.77 美元，200 日简单移动平均线为 3.22 美元。</p>
<p>Aclaris Therapeutics（纳斯达克：ACRS - 获取免费报告）最后一次发布季度财报是在 2 月 26 日，生物技术公司报告每股收益（EPS）为-0.16 美元，低于分析师的共识预期-0.15 美元，差距为 0.01 美元。该公司季度收入为 130 万美元，而分析师预期为 207 万美元。Aclaris Therapeutics 的股本回报率为-52.04%，净利润率为-829.58%。作为一个整体，研究分析师预测 Aclaris Therapeutics 在当前财年将发布-0.63 的每股收益。</p>
<h2>内部人士下注</h2>
<p>在其他 Aclaris Therapeutics 的新闻中，主要股东 Braden Michael Leonard 在 4 月 23 日的交易中出售了 300,000 股该公司的股票。该股票以平均价格 4.53 美元出售，总交易额为 1,359,000.00 美元。出售完成后，内部人士持有该公司 13,950,000 股股票，估值约为 63,193,500 美元。此次交易使其持股比例减少了 2.11%。该交易已在与证券交易委员会的法律文件中披露，相关文件可通过此链接访问。内部人士持有该公司 5.60% 的股票。</p>
<h2>机构资金流入和流出</h2>
<p>对冲基金和其他机构投资者最近买卖了该公司的股票。摩根大通在第三季度将其在 Aclaris Therapeutics 的持仓增加了 21.6%。摩根大通现在持有 758,576 股该生物技术公司的股票，价值 1,441,000 美元，在此期间又购买了 134,784 股。AXQ Capital LP 在第三季度购买了 Aclaris Therapeutics 的新头寸，价值约 27,000 美元。纽约梅隆银行在第一季度将其在 Aclaris Therapeutics 的持仓增加了 1.7%。纽约梅隆银行现在持有 207,024 股该生物技术公司的股票，价值 776,000 美元，在上个季度又购买了 3,507 股。SG Americas Securities LLC 在第一季度将其在 Aclaris Therapeutics 的持仓增加了 73.6%。SG Americas Securities LLC 现在持有 26,767 股该生物技术公司的股票，价值 100,000 美元，在上个季度又收购了 11,344 股。最后，Strs Ohio 在第一季度获得了 Aclaris Therapeutics 的新头寸，价值约 60,000 美元。98.34% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Aclaris Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Aclaris Therapeutics, Inc（纳斯达克：ACRS）是一家临床阶段的生物制药公司，专注于发现、开发和商业化用于皮肤病和相关罕见疾病的新型小分子疗法。该公司的产品管线包括多个旨在解决慢性炎症性皮肤病和非黑色素瘤皮肤病变的候选药物。主要项目包括 ATI-50002，一种用于去除传染性软疣的外用药物，ATI-50003 用于治疗寻常疣，ATI-1501，一种针对瘙痒性疾病的口服 JAK1/2 抑制剂，以及 ATI-450，一种用于炎症适应症的口服 MK2 抑制剂。</p>
<p>Aclaris 成立于 2016 年，总部位于宾夕法尼亚州马尔文，利用专有化学平台和转化研究能力推进多个临床和前临床候选药物。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Aclaris Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNSUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNSUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Aclaris Therapeutics 吗？</h2>
<p>在你考虑 Aclaris Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Aclaris Therapeutics 并不在名单上。</p>
<p>虽然 Aclaris Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ACRS

医疗业 ETF - Vanguard

医疗业 ETF - SPDR

<p>Guggenheim 将 Aclaris Therapeutics (NASDAQ: ACRS) 的评级上调至 “强力买入”。该股票在分析师中获得了混合评级，其中两位给予强力买入，五位给予买入，一位给予卖出。Aclaris 的市值为 6.6339 亿美元，当前价格为 4.75 美元，年内最高价为 4.89 美元。该公司报告的季度每股收益亏损为 0.16 美元，未能达到预期。最近的内部交易中，主要股东 Braden Michael Leonard 出售了 300,000 股。机构投资者持有该股票的 98.34%，显示出强烈的机构兴趣</p>

<p>Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) was upgraded by investment analysts at Guggenheim to a &#34;strong-buy&#34; rating in a report released on Monday,Zacks.com reports.</p>
<div class="lb-trans"><p>Aclaris Therapeutics（纳斯达克股票代码：ACRS - 获取免费报告）在周一发布的报告中被 Guggenheim 的投资分析师上调至 “强力买入” 评级，Zacks.com 报道。</p>
</div><p>Get <strong>Aclaris Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Aclaris Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只被低估的制药股，具备上涨催化剂</li>
</ul>
</div><p>ACRS has been the topic of several other reports. Wall Street Zen downgraded Aclaris Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Sunday, April 12th. Piper Sandler increased their price target on Aclaris Therapeutics from $7.00 to $11.00 and gave the stock an &#34;overweight&#34; rating in a report on Tuesday. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Aclaris Therapeutics in a research report on Friday, March 27th. UBS Group set a $10.00 price target on shares of Aclaris Therapeutics in a report on Thursday, April 16th. Finally, Craig Hallum began coverage on Aclaris Therapeutics in a research note on Friday, January 30th. They issued a &#34;buy&#34; rating and a $10.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of &#34;Buy&#34; and an average price target of $11.00.</p>
<div class="lb-trans"><p>ACRS 已经成为其他几份报告的主题。华尔街 Zen 在 4 月 12 日的研究报告中将 Aclaris Therapeutics 的评级从 “持有” 下调至 “卖出”。Piper Sandler 在周二将 Aclaris Therapeutics 的目标价从 7.00 美元上调至 11.00 美元，并给予该股票 “超配” 评级。Weiss Ratings 在 3 月 27 日的研究报告中重申了对 Aclaris Therapeutics 的 “卖出（d-）” 评级。瑞银集团在 4 月 16 日的报告中设定了 Aclaris Therapeutics 的目标价为 10.00 美元。最后，Craig Hallum 在 1 月 30 日的研究报告中开始覆盖 Aclaris Therapeutics。他们给予该公司 “买入” 评级和 10.00 美元的目标价。两位股票研究分析师给予该股票 “强力买入” 评级，五位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “买入”，平均目标价为 11.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on ACRS</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ACRS 的最新股票分析</strong></p>
</div><h2>Aclaris Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Aclaris Therapeutics 股票表现</h2>
</div><p>Shares of NASDAQ:ACRS opened at $4.75 on Monday. Aclaris Therapeutics has a one year low of $1.16 and a one year high of $4.89. The stock has a market capitalization of $663.39 million, a price-to-earnings ratio of -8.96 and a beta of 0.76. The company has a 50-day simple moving average of $3.77 and a 200-day simple moving average of $3.22.</p>
<div class="lb-trans"><p>纳斯达克：ACRS 的股票在周一开盘价为 4.75 美元。Aclaris Therapeutics 的年低为 1.16 美元，年高为 4.89 美元。该股票的市值为 6.6339 亿美元，市盈率为-8.96，贝塔值为 0.76。该公司 50 日简单移动平均线为 3.77 美元，200 日简单移动平均线为 3.22 美元。</p>
</div><p>Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.01). The company had revenue of $1.30 million for the quarter, compared to analysts' expectations of $2.07 million. Aclaris Therapeutics had a negative return on equity of 52.04% and a negative net margin of 829.58%. As a group, research analysts forecast that Aclaris Therapeutics will post -0.63 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Aclaris Therapeutics（纳斯达克：ACRS - 获取免费报告）最后一次发布季度财报是在 2 月 26 日，生物技术公司报告每股收益（EPS）为-0.16 美元，低于分析师的共识预期-0.15 美元，差距为 0.01 美元。该公司季度收入为 130 万美元，而分析师预期为 207 万美元。Aclaris Therapeutics 的股本回报率为-52.04%，净利润率为-829.58%。作为一个整体，研究分析师预测 Aclaris Therapeutics 在当前财年将发布-0.63 的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Aclaris Therapeutics news, major shareholder Braden Michael Leonard sold 300,000 shares of the business's stock in a transaction dated Thursday, April 23rd. The stock was sold at an average price of $4.53, for a total transaction of $1,359,000.00. Following the completion of the sale, the insider owned 13,950,000 shares of the company's stock, valued at approximately $63,193,500. The trade was a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Insiders own 5.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Aclaris Therapeutics 的新闻中，主要股东 Braden Michael Leonard 在 4 月 23 日的交易中出售了 300,000 股该公司的股票。该股票以平均价格 4.53 美元出售，总交易额为 1,359,000.00 美元。出售完成后，内部人士持有该公司 13,950,000 股股票，估值约为 63,193,500 美元。此次交易使其持股比例减少了 2.11%。该交易已在与证券交易委员会的法律文件中披露，相关文件可通过此链接访问。内部人士持有该公司 5.60% 的股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase &amp; Co. boosted its position in Aclaris Therapeutics by 21.6% during the 3rd quarter. JPMorgan Chase &amp; Co. now owns 758,576 shares of the biotechnology company's stock worth $1,441,000 after purchasing an additional 134,784 shares during the period. AXQ Capital LP purchased a new position in Aclaris Therapeutics in the third quarter valued at about $27,000. Bank of New York Mellon Corp grew its position in shares of Aclaris Therapeutics by 1.7% during the first quarter. Bank of New York Mellon Corp now owns 207,024 shares of the biotechnology company's stock worth $776,000 after buying an additional 3,507 shares in the last quarter. SG Americas Securities LLC grew its holdings in Aclaris Therapeutics by 73.6% during the 1st quarter. SG Americas Securities LLC now owns 26,767 shares of the biotechnology company's stock worth $100,000 after acquiring an additional 11,344 shares in the last quarter. Finally, Strs Ohio acquired a new position in Aclaris Therapeutics in the first quarter worth about $60,000. 98.34% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近买卖了该公司的股票。摩根大通在第三季度将其在 Aclaris Therapeutics 的持仓增加了 21.6%。摩根大通现在持有 758,576 股该生物技术公司的股票，价值 1,441,000 美元，在此期间又购买了 134,784 股。AXQ Capital LP 在第三季度购买了 Aclaris Therapeutics 的新头寸，价值约 27,000 美元。纽约梅隆银行在第一季度将其在 Aclaris Therapeutics 的持仓增加了 1.7%。纽约梅隆银行现在持有 207,024 股该生物技术公司的股票，价值 776,000 美元，在上个季度又购买了 3,507 股。SG Americas Securities LLC 在第一季度将其在 Aclaris Therapeutics 的持仓增加了 73.6%。SG Americas Securities LLC 现在持有 26,767 股该生物技术公司的股票，价值 100,000 美元，在上个季度又收购了 11,344 股。最后，Strs Ohio 在第一季度获得了 Aclaris Therapeutics 的新头寸，价值约 60,000 美元。98.34% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Aclaris Therapeutics</h2>
<div class="lb-trans"><h2>关于 Aclaris Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Aclaris Therapeutics, Inc NASDAQ: ACRS is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company's pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.</p>
<div class="lb-trans"><p>Aclaris Therapeutics, Inc（纳斯达克：ACRS）是一家临床阶段的生物制药公司，专注于发现、开发和商业化用于皮肤病和相关罕见疾病的新型小分子疗法。该公司的产品管线包括多个旨在解决慢性炎症性皮肤病和非黑色素瘤皮肤病变的候选药物。主要项目包括 ATI-50002，一种用于去除传染性软疣的外用药物，ATI-50003 用于治疗寻常疣，ATI-1501，一种针对瘙痒性疾病的口服 JAK1/2 抑制剂，以及 ATI-450，一种用于炎症适应症的口服 MK2 抑制剂。</p>
</div><p>Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.</p>
<div class="lb-trans"><p>Aclaris 成立于 2016 年，总部位于宾夕法尼亚州马尔文，利用专有化学平台和转化研究能力推进多个临床和前临床候选药物。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Aclaris Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Aclaris Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNSUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ACRS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aclaris Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Aclaris Therapeutics 吗？</h2>
</div><p>Before you consider Aclaris Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Aclaris Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aclaris Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Aclaris Therapeutics 并不在名单上。</p>
</div><p>While Aclaris Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Aclaris Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Guggenheim

Market Beat

Aclaris Therap

Invesco Nasdaq Biotechnology ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

标普生物技术 3 倍做多 - Direxion

医药突破 ETF - ALPS

基因改革 ETF - ARK

标普全球医疗股指数 ETF - iShares

标普生物技术 ETF - SPDR

美国制药 ETF - iShares

Piper Sandler Cos

瑞银集团

纳斯达克 OMX 交易所

摩根大通

纽约梅隆银行

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

BANK OF NEW YORK MELLON CORP DEP SHS REPG 1/4000TH INT SER K PFD

Aclaris Therapeutics（纳斯达克股票代码：ACRS）的股票评级被 Guggenheim 上调